Urteste SA
WSE:URT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Urteste SA
WSE:URT
|
PL |
|
M
|
Monogram Orthopaedics Inc
NASDAQ:MGRM
|
US |
|
N
|
Numinus Wellness Inc
TSX:NUMI
|
CA |
|
Ashoka Buildcon Ltd
NSE:ASHOKA
|
IN |
|
C
|
Card Factory PLC
OTC:CRFCF
|
UK |
|
S
|
Salee Industry PCL
SET:SALEE
|
TH |
Urteste SA
Urteste SA specializes in the development of technology that allows the detection of cancers at early stages of their development. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-10-27. The firm operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The firm offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.
Urteste SA specializes in the development of technology that allows the detection of cancers at early stages of their development. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-10-27. The firm operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The firm offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.
